Direct thrombin inhibitors in patients with mechanical heart valves: Ready for clinical trials?

Hans-Jürgen Rupprecht

doi:10.1160/TH09-05-0279

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(06): 995-996
DOI: 10.1160/TH09-05-0279

Editorial Focus

Schattauer GmbH

Direct thrombin inhibitors in patients with mechanical heart valves: Ready for clinical trials?

Hans-Jürgen Rupprecht

¹II. Medizinische Klinik, GPR Klinikum Rüsselsheim, Rüsselsheim, Germany

› Author Affiliations

Abstract

Full Text

References

References
1 Crouch MA, Kasirajan V, Cahoon W. et al. Successful use and dosing of bivalirudin after temporary total artificial heart implantation: a case series. Pharmaco-therapy 2008; 28: 1413-1420.
2 Koster A, Dyke CM, Lincoff AM. et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Throrac Surg 2007; 83: 572-577.
3 Mahaffey KW, Lewis BE, Wildermann NM. et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention inpatients with heparin induces thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 2003; 15: 611-616.
4 Lewis BE, Wallis DE, Kelton JG. et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163: 1849-1856.
5 Lewis BE, Wallis DE, Hursting MJ. et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 2006; 129: 1167-1175.
6 Maegdefessel L, Linde T, Michel T. et el. Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves, results of an in-vitro study. Thromb Haemost 2009; 101: 1163-1169.
7 Blat Y, Seiffert D. A renaissance for the contact system in blood coagulation. Thromb Haemost 2008; 99: 457-460.
8 Nielsen VG, Steenwyk BL, Gurley WQ. et al. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro . J heart Lung Transplant 2006; 25: 653-663.
9 Tanaka KA, Szlam F, Sun HY. et al. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. Anest Analg 2007; 105: 933-939.